Corrects adjusted EPS to $1.05 from $1.27 in Key Details table
Overview
Turning Point Q3 net sales rise 31.2% yr/yr, beating analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting robust performance
Company raises full-year 2025 Adjusted EBITDA and Modern Oral sales guidance
Outlook
Turning Point raises 2025 Adjusted EBITDA guidance to $115.0 – 120.0 mln
Company increases full-year Modern Oral sales guidance to $125.0 – 130.0 mln
Result Drivers
MODERN ORAL GROWTH - Modern Oral sales surged 628% yr/yr to $36.7 mln, now 30.8% of total sales
STOKER'S SEGMENT - Stoker's segment net sales rose 80.8% yr/yr, driven by Modern Oral and MST growth
ZIG-ZAG DECLINE - Zig-Zag segment net sales fell 10.5% yr/yr, but excluding Clipper, rose mid-single-digits sequentially
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $118.97 mln | $111.40 mln (5 Analysts) |
Q3 Adjusted EPS | Beat | $1.05 | $0.87 (3 Analysts) |
Q3 Net Income | $23.75 mln | ||
Q3 Gross Profit | $70.42 mln | ||
Q3 Operating income | $25.88 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the tobacco peer group is "buy"
Wall Street's median 12-month price target for Turning Point Brands Inc is $109.00, about 12.7% above its November 4 closing price of $95.18
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 22 three months ago
Press Release: ID:nBwbxnjPVa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)